In:
Journal of Cutaneous Pathology, Wiley, Vol. 49, No. 11 ( 2022-11), p. 978-987
Abstract:
Programmed cell death protein (PD‐1) and programmed death‐ligand 1 (PD‐L1) inhibition checkpoint blockade leads to various cutaneous adverse reactions, including bullous pemphigoid and lichen‐planus‐like reactions. However, lichen planus pemphigoides (LPP), manifesting histopathologic features of both lichen planus and bullous pemphigoid, has more rarely been associated with immunotherapy. Methods The clinical and histopathologic findings of three patients were examined, and a review of cases of LPP and bullous lichen planus secondary to PD‐1 inhibitor therapy was performed. Results Three patients (two with advanced non‐small‐cell lung adenocarcinoma and the third with metastatic breast cancer) presented with both lichenoid eruptions and bullae. Biopsy of the lesions revealed lichenoid tissue reactions in all three patients. Together with the histopathologic findings, direct immunofluorescence (DIF) showing linear C3 and IgG deposition and positive enzyme‐linked immunosorbent assay (ELISA) showing BP180 positivity supported a diagnosis of LPP in two patients. The third patient in our series also showed confirmatory ELISA testing supporting LPP. Conclusions Lichen planus pemphigoides is a distinct cutaneous toxicity to checkpoint inhibitor therapy illustrates a possible pathogenic mechanism and the importance of dermatopathology recognition to render an accurate diagnosis.
Type of Medium:
Online Resource
ISSN:
0303-6987
,
1600-0560
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2018100-0
